Guideline for the management of knee and hip osteoarthritis

Administrative report
Guideline for the management of knee and hip osteoarthritis: Administrative report

Disclaimer

The information set out in this publication is current at the date of first publication and is intended for use as a guide of a general nature only and may or may not be relevant to particular patients or circumstances. Nor is this publication exhaustive of the subject matter. Persons implementing any recommendations contained in this publication must exercise their own independent skill or judgement or seek appropriate professional advice relevant to their own particular circumstances when so doing. Compliance with any recommendations cannot of itself guarantee discharge of the duty of care owed to patients and others coming into contact with the health professional and the premises from which the health professional operates.

Accordingly, The Royal Australian College of General Practitioners Ltd (RACGP) and its employees and agents shall have no liability (including without limitation liability by reason of negligence) to any users of the information contained in this publication for any loss or damage (consequential or otherwise), cost or expense incurred or arising by reason of any person using or relying on the information contained in this publication and whether caused by reason of any error, negligent act, omission or misrepresentation in the information.

Recommended citation


The Royal Australian College of General Practitioners Ltd
100 Wellington Parade
East Melbourne, Victoria 3002
Tel 03 8699 0414
Fax 03 8699 0400
www.racgp.org.au

ABN: 34 000 223 807

Published July 2018

© The Royal Australian College of General Practitioners 2018

This resource is provided under licence by the RACGP. Full terms are available at www.racgp.org.au/usage/licence. In summary, you must not edit or adapt it or use it for any commercial purposes. You must acknowledge the RACGP as the owner.

We acknowledge the Traditional Custodians of the lands and seas on which we work and live, and pay our respects to Elders, past, present and future.
Guideline for the management of knee and hip osteoarthritis

Administrative report
Contents

1. Responsible organisation 1
2. Source of funding 1
3. Guideline development working group 1
   3.1 Process and criteria for selection of members 1
   3.2 Members of the working group and declarations of interests 2
4. Development of recommendations 6
5. Conflicts of interest 6
6. Terms of reference 6
   6.1 Co-chair responsibilities 6
   6.2 Working group member responsibilities 6
7. Public consultation 7
1. Responsible organisation

The update, publication and dissemination of the Guideline for the management of knee and hip osteoarthritis (OA guideline) was coordinated by The Royal Australian College of General Practitioners (RACGP).

2. Source of funding

The development of the OA guideline is funded in part by Medibank Better Health Foundation. Medibank Better Health Foundation provided $66,667 in support for development of systematic literature reviews, data extraction and compilation of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) summary report.

3. Guideline development working group

The guideline is intended for use by general practitioners (GPs) in primary care settings. An expert multidisciplinary working group was convened, comprising health professionals representing all disciplines relevant to settings in which patients with osteoarthritis (OA) may seek treatment. This working group ensured the robust and transparent development of the guideline in accordance with National Health and Medical Research Council (NHMRC) guideline processes. The working group is co-chaired by Professor David Hunter and Professor Kim Bennell.

3.1 Process and criteria for selection of members

During the planning stages of the project, the RACGP project team and co-chairs identified key stakeholder groups and individuals who should be involved in the development. This included relevant health professionals involved in all aspects of OA treatment, management, research, guidelines or standards development, and consumer representatives. Some members were nominated by their relevant professional organisations to represent the discipline, or identified by relevant consumer organisations as the organisational representative or as an individual with a musculoskeletal condition. Members were invited to join the working group by the chair.

Working group members provided the views of, and advocated for, the relevant disciplines, and participated in the decision-making process for the recommendations. This ensures all perspectives are considered and incorporated in the development of the guideline.

The multidisciplinary working group comprised representatives from:

- general practice
- rheumatology
- physiotherapy
- orthopaedic surgery
- sport and exercise medicine
- rehabilitation medicine
- consumer representation (individual and consumer organisation)
- academic research
- Medibank Better Health Foundation.
3.2 Members of the working group and declarations of interests

The co-chairs and working group members participated in the development of the guideline as detailed in section 6: Terms of reference.

<table>
<thead>
<tr>
<th>Name</th>
<th>Relevant discipline</th>
<th>Declarations of interest</th>
<th>Conflict management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Professor David Hunter</strong></td>
<td>Rheumatology</td>
<td>• Merck Serono</td>
<td>Did not participate in discussion and formulating recommendations for fibroblast</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Flexion</td>
<td>growth factor, platelet-rich plasma, stem cell therapy, realigning patellofemoral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DonJoy Braces</td>
<td>braces</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Research with no remuneration in assistive walking devices, valgus unloading/realignment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>braces, weight management, glucosamine, chondroitin, weight management and exercise</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Submitted research grant on stem cell therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Conducted systematic review on glucosamine</td>
<td></td>
</tr>
<tr>
<td><strong>Professor Kim Bennell</strong></td>
<td>Physiotherapy</td>
<td>• Secretary General, Osteoarthritis Research Society</td>
<td>Did not participate in discussion and formulating recommendations for platelet-rich</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• International editorial board member, Osteoarthritis and Cartilage</td>
<td>plasma, unloading shoes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Research with no remuneration in physical activity, muscle strengthening, taping,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>assistive walking devices, behavioural therapy, lateral wedged insoles, minimista</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>footprint, unstable shoes, acupuncture, cognitive behavioural therapy and exercise</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Commercial interest in unloading shoes</td>
<td></td>
</tr>
<tr>
<td><strong>Professor Michael Austin</strong></td>
<td>Consumer representative with osteoarthritis</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td><strong>Professor Andrew Briggs</strong></td>
<td>Physiotherapy</td>
<td>• Director, HealthSense Aust Pty Ltd</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Member, Australian Physiotherapy Association</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Project lead, Victorian Osteoarthritis Model of Care project, under the auspices of</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>the Victorian Musculoskeletal Clinical Leadership project supported by the Department</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>of Health and Human Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Member of the guidelines development group for the Therapeutic Guidelines: Rheumatology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Version 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Developed the Australian Commission on Safety and Quality in Health Care Osteoarthritis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>of the knee clinical care standard – The case for improvement</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Research with no remuneration in physical activity, muscle strengthening</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Members and declaration of interests

<table>
<thead>
<tr>
<th>Name</th>
<th>Relevant discipline</th>
<th>Declarations of interest</th>
<th>Conflict management</th>
</tr>
</thead>
</table>
| **Professor Rachelle Buchbinder**         | Rheumatology        | • President, Australian Rheumatology Association (ARA)  
• Chair, Knee Osteoarthritis Clinical Care Standard Topic Working Group, for the Australian Commission on Safety and Quality in Health Care (2015–16)  
• Member, Medical Services Advisory Committee (MSAC) (2016–present)  
• Member, Medicare Benefits Schedule (MBS) Review: Imaging of the Knee Working Group (2015–16)  
• Member, Writing Group (2015–16), Therapeutic Guidelines: Rheumatology, Version 3  
• Founding member and chair, Executive Committee, Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trial Network  
• Member, Expert Committee (ARA nominee), Arthritis Australia Position Statement: Exercise for hip and/or knee osteoarthritis and rheumatoid arthritis  
• Member, Australian atlas of healthcare variation Expert Advisory Group on Knee Pain for the Australian Commission on Safety and Quality in Health Care; numerous papers published on this topic  
• Member, Working Group (2006–08) developing RACGP Primary care guidelines for the management of symptomatic osteoarthritis in adults  
• Research with no remuneration in extracorporeal shockwave therapy                                                                                   | Did not participate in discussion and formulating recommendation for platelet-rich plasma                                                                                                                                 |
| **Dr Stephen Bunker**                     | Medibank representative | None                                                                                                                                                                                                                   |                                                                                                                                                                                                                          |
| **Professor Peter Choong**               | Orthopaedic surgery | None                                                                                                                                                                                                                    |                                                                                                                                                                                                                          |

Director, Monash Department of Clinical Epidemiology, Cabrini Hospital, Malvern, Vic
Professor, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic

Chair of Surgery, and Head of Department of Surgery, University of Melbourne at St Vincent's Hospital, Melbourne, Vic
Director of Orthopaedics, St Vincent's Hospital, Melbourne, Vic
Chair, Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Centre, Melbourne, Vic
### Table 1. Members and declaration of interests

<table>
<thead>
<tr>
<th>Name</th>
<th>Relevant discipline</th>
<th>Declarations of interest</th>
<th>Conflict management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Dan Ewald</td>
<td>General practice</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Professor Kieran Fallon</td>
<td>Sport and exercise medicine</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Mr Ben Harris</td>
<td>Consumer organisational representative</td>
<td>MOVE receives funding from Pfizer, Abbvie</td>
<td>Did not participate in discussion and formulating recommendations for TNF-α, anti-NGF inhibitors, methotrexate</td>
</tr>
<tr>
<td>Professor Rana Hinman</td>
<td>Physiotherapy</td>
<td>• Editorial board member, <em>Physical Therapy</em> (USA)</td>
<td>Did not participate in discussion and formulating recommendation for unloading shoes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Member, Australian Physiotherapy Association</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Member, Association of Rheumatology Health Professionals (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Research with no remuneration in physical activity, muscle strengthening, taping, assistive walking devices, behavioural therapy, lateral wedged insoles, minimalist footwear, unstable shoes, patellar taping, acupuncture</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Commercial interest in unloading shoes</td>
<td></td>
</tr>
<tr>
<td>Dr Leonie Katekar</td>
<td>Medibank representative</td>
<td>Board Member, East Melbourne Primary Health Network</td>
<td></td>
</tr>
</tbody>
</table>
### Table 1. Members and declaration of interests

<table>
<thead>
<tr>
<th>Name</th>
<th>Relevant discipline</th>
<th>Declarations of interest</th>
<th>Conflict management</th>
</tr>
</thead>
</table>
| **Associate Professor Marie Pirotta**  
General practitioner  
Employee at Health Services Commission, Melbourne, Vic  
Associate Professor, Department of General Practice, University of Melbourne, Vic | General practice | • Member, Australian Medical Association  
• Member, Australian Association of Academic Primary Care  
• Board member, Management of Rosary Homes  
• Education grant, Amgen  
• Research with no remuneration in acupuncture |                                                                                       |
| **Dr Michael Ponsford**  
Rehabilitation medicine specialist, Epworth Hospital, Richmond, Vic | Rehabilitation medicine | None                                                                                     |                                                                                       |
| **Associate Professor Morton Rawlin**  
General practitioner, Macedon Medical Centre, Manningham, Vic | General practice | • Medical Director, Royal Flying Doctor Service Victoria  
• Board member, Rural Workforce Agency Victoria  
• Chair, General Practice Mental Health Standards Collaboration (GPMHSC)  
• Board member, Mental Health Professionals’ Network (MHPN)  
• Chair, Dermatology network, RACGP |                                                                                       |
| **Dr Xia Wang**  
Epidemiologist, University of Sydney, NSW | Epidemiology | Submitted research grant on stem cell therapy | Did not participate in discussion and formulating recommendation for stem cell therapy |
| **Dr Samuel Whittle**  
Senior consultant rheumatologist, Queen Elizabeth Hospital, Woodville South, SA | Rheumatology | • Honorary Treasurer, Australian Rheumatology Association  
• Member, Executive Working Group, Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network  
• Travel support, consultancy or speaker fees in last 12 months from Novartis, Pfizer, Janssen |                                                                                       |
4. Development of recommendations

The guideline working group is chaired by two experts in the OA field, Professor David Hunter and Professor Kim Bennell. Medibank Better Health Foundation has clinical representatives on this multidisciplinary working committee. Input is provided by the working group, with discussions and recommendations, and potentially controversial issues discussed. Decisions are agreed upon by the entire committee. A voting system ensures consensus agreement once the recommendations are confirmed. To ensure conflict of interest procedures were upheld, all clinical representatives (including those from Medibank) were excluded from the development of recommendations on topics where it was agreed there may be a real or perceived conflict of interest. Members and declarations of interest are listed in Table 1 of this administrative report. The method used to formulate and arrive at consensus-based recommendations is described in section 2.4 of the OA guideline.

5. Conflicts of interest

This guideline has been produced in accordance with the rules and processes outlined in the RACGP Conflict of Interest Policy.

Conflict of interest (COI) disclosures are available in Table 1.

All working group members are required to complete a COI register of actual, potential and perceived COI as part of the RACGP Conflict of Interest Policy. Declarations in this register include membership of committees, potential COI from different sources of income, office holder, trusteeship, agreements and other interests, and any other relevant issues that may be a reason for potential conflicts of interest.

COI declaration is a standing item in the agenda for all meetings. At the request of the chair, COI is declared and noted at the start of the meeting. In addition, individuals must disclose any relevant interests relating to an intervention prior to commencement of discussion for the intervention, which is captured in the minutes of the meeting. All members must disclose COI in any matter being considered for a decision. Any member with a COI must not participate, directly or indirectly, in a decision on the matter. If a member declared a conflict in relation to a specific intervention (with the exception of conducting research), the member did not participate in the discussion or decision-making for the intervention.

6. Terms of reference

6.1 Co-chair responsibilities

- Agree on the preliminary scope and project approach
- Work with RACGP project staff to identify appropriate members of the working group, help direct the necessary literature searches and other relevant tasks
- Liaise with the RACGP project staff to ensure the project is delivered on time and within specifications, and attend all meetings
- Responsibilities of working group member as per below

6.2 Working group member responsibilities

- Identify the key questions to be answered using the PICO (patient/population/problem, intervention, comparison/control, outcome) format
- Develop content and recommendations
• Through consensus (Delphi survey), agree on inclusion or exclusion of content
• Develop additional resources, such as the summary of recommendations and/or treatment algorithm
• Complete and fulfil all relevant legal agreements, including the COI declaration
• Review input/feedback from all relevant stakeholders
• Providing timely updates to the working group and RACGP project staff when required
• Respond to project communication via email or meeting in a timely manner
• Attend meetings

7. Public consultation

The guideline was released for public consultation from 20 November 2017 to 20 December 2017. The public consultation was published and promoted via the RACGP website and RACGP social media channels, and by the NHMRC via NHMRC Health Tracker.

Invitations were sent to relevant federal and state government agencies, including the Australian Government Department of Health Chief Medical Officer and state chief health officers. The consultation documents were also sent via email to a wide range of experts and potential users identified by the project team and working group.

Key internal stakeholders invited to provide submissions:
• RACGP Aboriginal and Torres Strait Islander Health faculty
• RACGP Specific Interests Integrative Medicine working group
• RACGP Specific Interests Musculoskeletal Medicine network
• RACGP Specific Interests Pain Management network
• RACGP Specific Interests Sports and Exercise Medicine network

Key external stakeholders invited to provide submissions included:
• Arthritis Australia
• Australian Commission on Safety and Quality in Health Care
• Australian Orthopaedic Association
• Australian Physiotherapy Association
• Australian Primary Care Nurses Association
• Australian Psychological Society
• Australian Rheumatology Association (of the Royal Australasian College of Physicians)
• Australasian College of Sports and Exercise Medicine Physicians
• Consumers Health Forum of Australia
• Dietitians Association of Australia
• Exercise and Sports Science Australia
• Faculty of Rehabilitation Medicine, Royal Australasian College of Physicians
• MOVE muscle, bone & joint health
• Occupational Therapy Australia
• Painaustralia
Submissions to the public consultation were received from professional organisations as well as individuals from a diverse range of disciplines. The de-identified public consultation summary accompanies the guideline.

Submissions were received from:

- Arthritis Australia
- Australian Acupuncture & Chinese Medicine Association Ltd
- Australasian College of Sports and Exercise Physicians
- Australian Commission on Safety and Quality in Health Care
- Australian Medicines Handbook
- Australian Physiotherapy Association
- Australian Psychological Society
- Deputy Chief Medical Officer, Australian Government Department of Health
- Dietitians Association of Australia
- Halyard Health
- Musculoskeletal Network, NSW Agency for Clinical Innovation
- NPS MedicineWise
- Occupational Therapy Australia
- Painaustralia
- Representative from Queensland Health
- Representatives from RACGP Expert Committees, RACGP Specific Interests Musculoskeletal Medicine network, RACGP Specific Interests Pain Management network, RACGP Specific Interests Sports and Exercise Medicine network, RACGP Specific Interests Integrative Medicine working group
- Individual GPs, healthcare practitioners including rheumatologists, specialist pain physicians, musculoskeletal medicine practitioners, sports physicians, musculoskeletal and sports physiotherapists, pharmacists and accredited exercise physiologists
Healthy Profession.
Healthy Australia.